

AACR Special Conference: Tumor Immunology and Immunotherapy
November 27-30, 2018 • Loews Miami Beach Hotel • Miami Beach, Florida

CONFERENCE PROGRAM

Tuesday, November 27

- | | |
|----------------------------|---|
| 5:00 p.m.-7:00 p.m. | Opening Keynote Lectures |
| 5:00 p.m.-6:00 p.m. | Turning the heat up on pancreatic cancer: Lessons on overcoming a “cold” immunologic microenvironment
Elizabeth M. Jaffee, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD |
| 6:00 p.m.-7:00 p.m. | Precision CAR T therapy
Carl H. June, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA |
| 7:00 p.m.-9:00 p.m. | Opening Reception |

Wednesday, November 28

- | | |
|-----------------------------|---|
| 7:00 a.m.-8:00 a.m. | Breakfast |
| 8:00 a.m.-10:30 a.m. | Plenary Session 1: Microbiome Influences on Cancer Development and Response to Therapy
Session Chair: Jennifer Wargo , The University of Texas MD Anderson Cancer Center, Houston, TX |
| 8:00 a.m.-8:30 a.m. | The role of the microbiome in response to cancer therapy
Jennifer Wargo |
| 8:30 a.m.-9:00 a.m. | The microbiome associations of colon cancer
Cynthia L. Sears, Johns Hopkins University School of Medicine, Baltimore, MD |
| 9:00 a.m.-9:15 a.m. | Leveraging gut microbiota networks to impact tumor immunotherapy*
Lata Jayaraman, Seres Therapeutics, Cambridge, MA |
| 9:15 a.m.-9:30 a.m. | <i>Bacteroides fragilis</i> toxin-induced epithelial-mesenchymal transition and stem-like phenotype in breast epithelial cells and concomitantly activated Notch1 and βcatenin axes*
Sheetal Parida, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD |

AACR Special Conference: Tumor Immunology and Immunotherapy
November 27-30, 2018 • Loews Miami Beach Hotel • Miami Beach, Florida

- 9:30 a.m.-10:00 a.m. **Microbiota: Key modulator of the tumor microenvironment**
Romina Goldszmid, NIH, Bethesda, MD
- 10:00 a.m.-10:30 a.m. **Tumor and host factors regulating antitumor immunity and immunotherapy efficacy**
Thomas Gajewski, The University of Chicago, Chicago, IL
- 10:30 a.m.-11:00 a.m. Break**
- 11:00 a.m.-1:00 p.m. Plenary Session 2: Tools for Discovery: Systems Biology and High-Density Analytics**
Session Chair: Paul G. Thomas, St. Jude Children's Research Hospital, Memphis, TN
- 11:00 a.m.-11:30 a.m. **Hitting the target: T-cell receptors, cross-reactivity, and tumors**
Paul G. Thomas
- 11:30 a.m.-11:45 a.m. **Immuno-mass spectrometric identification of serum biomarkers of response and toxicity to pembrolizumab***
Milena Music, University of Toronto, Toronto, ON, Canada
- 11:45 a.m.-12:00 p.m. **Single-cell analysis illuminates dysfunctional CD8⁺ T cells as a proliferative, dynamically regulated compartment within human melanoma***
Ido Yofe, Weizmann Institute of Science, Rehovot, Israel
- 12:00 p.m.-12:30 p.m. **Learning the rules of human cancer immunity**
Nir Hacohen, Broad Institute/Massachusetts General Hospital, Charlestown, MA
- 12:30 p.m.-1:00 p.m. **Using high-dimensional machine-assisted analysis for biomarkers detection and guidance of immunotherapy to cancer**
Carsten Krieg, Medical University of South Carolina, Charleston, SC
- 1:00 p.m.-3:30 p.m. Lunch and Poster Session A**
- 3:30 p.m.-6:00 p.m. Plenary Session 3: Metabolic Regulation in Tumors: Implications for Therapy**
Session Chair: Matthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
- 3:30 p.m.-4:00 p.m. **Metabolic regulation of cell proliferation**
Matthew G. Vander Heiden

AACR Special Conference: Tumor Immunology and Immunotherapy
November 27-30, 2018 • Loews Miami Beach Hotel • Miami Beach, Florida

- 4:00 p.m.-4:30 p.m. **The LXR/ApoE pathway regulates the innate immune system in cancer**
Masoud Tavazoie, Rgenix, Inc., New York, NY
- 4:30 p.m.-4:45 p.m. **Blockage of AHR activation by IDO/TDO-derived kynurenine restricts cancer immune suppression***
Luis Felipe Campesato, Memorial Sloan Kettering Cancer Center, New York, NY
- 4:45 p.m.-5:15 p.m. **Fueling T cells in inflammation and cancer**
Jeffrey C. Rathmell, Vanderbilt University Medical Center, Nashville, TN
- 5:15 p.m.-5:45 p.m. **LC3-associated phagocytosis in inflammation and anticancer immunity**
Douglas R. Green, St. Jude Children's Research Hospital, Memphis, TN
- 5:45 p.m.** **Dinner on Own**

Thursday, November 29

- 7:00 a.m.-8:00 a.m.** **Breakfast**
- 8:00 a.m.-10:00 a.m.** **Plenary Session 4: Myeloid and Vascular Programs in Cancer: Key Regulators of Antitumor Immunity**
Session Chair: Matthew F. Krummel, University of California San Francisco, San Francisco, CA
- 8:00 a.m.-8:30 a.m. **The key role for IRF8+ dendritic cells in cancer immunity**
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY
- 8:30 a.m.-9:00 a.m. **Vascular reprogramming for enhancing cancer immunotherapy**
Michele De Palma, Swiss Federal Institute of Technology, Lausanne, Switzerland
- 9:00 a.m.-9:15 a.m. **Targeting CD47 as a novel immunotherapy for multiple myeloma***
Jennifer Sun, Washington University in St. Louis, St. Louis, MO
- 9:15 a.m.-9:30 a.m. **Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy***
Michael Klichinsky, University of Pennsylvania, Philadelphia, PA
(not eligible for CME credit)

AACR Special Conference: Tumor Immunology and Immunotherapy
November 27-30, 2018 • Loews Miami Beach Hotel • Miami Beach, Florida

- 9:30 a.m.-10:00 a.m. **Imaging a world beyond checkpoints: Classes of immune responses in cancer**
Matthew F. Krummel
- 10:00 a.m.-10:30 a.m. Break**
- 10:30 a.m.-1:00 p.m. Plenary Session 5: Novel Checkpoints for Tumor Immunity**
Session Chair: Elizabeth M. Jaffee, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD
- 10:30 a.m.-11:00 a.m. **Molecular mechanisms of T cell exhaustion and implications for immunotherapy**
E. John Wherry, University of Pennsylvania, Philadelphia, PA
- 11:00 a.m.-11:30 a.m. **The mechanistic basis of cancer immunotherapy**
Ira Mellman, Cancer Immunology, Genentech, Inc., South San Francisco, CA
- 11:30 a.m.-12:00 p.m. **Lymphatic vessels: Barriers to adaptive immunity in melanoma**
Amanda Lund, Oregon Health & Science University, Portland, OR
- 12:00 p.m.-12:15 p.m. **Discovery of immune regulators in primary human T cells using genome-wide CRISPR screens***
Julia Carnevale, University of California San Francisco, San Francisco, CA
- 12:15 p.m.-12:30 p.m. **ADU-S100 (MIW815) synergizes with checkpoint blockade to elicit an antitumor CD8⁺ T-cell response to control distal tumors***
Weiwen Deng, Aduro Biotech, Inc., Berkeley, CA
- 12:30 p.m.-1:00 p.m. **Immune checkpoint blockade in cancer therapy: New insights and opportunities, and prospects for cures**
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX
- 1:00 p.m.-2:30 p.m. Lunch on Own**
- 2:30 p.m.-5:00 p.m. Plenary Session 6: New Combinations and Biomarkers**
Session Chair: Sandra S. McAllister, Harvard Medical School, Boston, MA
- 2:30 p.m.-3:00 p.m. **From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy**
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX

AACR Special Conference: Tumor Immunology and Immunotherapy
November 27-30, 2018 • Loews Miami Beach Hotel • Miami Beach, Florida

- 3:00 p.m.-3:30 p.m. **Pharmacologic and physiologic processes that affect response to immunotherapy**
Sandra S. McAllister
- 3:30 p.m.-3:45 p.m. **Heterogeneous activation of multiple suppressive pathways by scRNAseq may underscore resistance to PD-1 therapy in metastatic castration-resistant prostate cancer***
Amy Moran, Oregon Health & Science University, Portland, OR
- 3:45 p.m.-4:00 p.m. **Tumor cell-intrinsic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer***
Jinyang Li, University of Pennsylvania, Philadelphia, PA
- 4:00 p.m.-4:30 p.m. **Marker-guided targeted therapy, PARP inhibitors, and novel post-translational modification of PD-L1**
Mien-Chie Hung, The University of Texas MD Anderson Cancer Center, Houston, TX
- 4:30 p.m.-5:00 p.m. **Understanding mechanisms for combination immunotherapy**
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY
- 5:00 p.m.-7:00 p.m. **Reception and Poster Session B**

Friday, November 30

- 7:00 a.m.-8:00 a.m. **Breakfast**
- 8:00 a.m.-9:30 a.m. **Special Session: Novel Targets, Pathways and Tools**
Session Chairs: Drew Pardoll, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD
- 8:00 a.m.-8:10 a.m. **Assessing in vivo mechanisms regulating the therapeutic activity of bi-specific T cell engager (BiTE®) molecules in immune-competent mice expressing a chimeric human/mouse CD3ε receptor***
Brian Belmontes, Amgen Discovery Research, Amgen Inc., Thousand Oaks, CA
(not eligible for CME credit)
- 8:10 a.m.-8:20 a.m. **Development of chimeric forms of IFN-alpha for “on demand” in vivo**

**AACR Special Conference: Tumor Immunology and Immunotherapy
November 27-30, 2018 • Loews Miami Beach Hotel • Miami Beach, Florida**

- cancer gene therapy***
Nadia Coltella, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy
- 8:20 a.m.-8:30 a.m. **CD123CAR displays clinical activity in relapsed/refractory (r/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study***
Lihua Budde, City of Hope National Medical Center, Duarte, CA
- 8:30 a.m.-8:40 a.m. **A novel NK cell-targeted therapeutic strategy against pancreatic cancer***
Kamiya Mehla, University of Nebraska Medical Center, Omaha, NE
- 8:40 a.m.-8:50 a.m. **RNA aptamers specific for tumor-infiltrating myeloid cells***
Dimitri Van Simaey, Sylvester Cancer Center, Miami, FL
- 8:50 a.m.-9:00 a.m. **Targeted blockade of FcγRIIB on dendritic cells and macrophages enhances cellular activation and Fc-dependent immune responses***
Ryan Molony, Novartis Institutes for BioMedical Research, Cambridge, MA
- 9:00 a.m.-9:10 a.m. **A novel immunomodulatory strategy of targeting glycol-immune checkpoints using EAGLE technology to treat cancer***
Li Peng, Palleon Pharmaceuticals, Waltham, MA
(not eligible for CME credit)
- 9:10 a.m.-9:20 a.m. **Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors***
Adrian Pelin, Ottawa Hospital Research Institute, Ottawa, ON, Canada
- 9:20 a.m.-10:00 a.m. Break**
- 10:00 a.m.-12:30 p.m. Plenary Session 7: Emerging Molecular and Cellular Targets**
Session Chair: Lisa M. Coussens, Oregon Health & Science University
Knight Cancer Institute, Portland, OR
- 10:00 a.m.-10:30 a.m. **Macrophage control of antitumor immunity**
Judith A. Varner, University of California San Diego, San Diego, CA
- 10:30 a.m.-10:45 a.m. **A novel combination immunotherapy with a vaccine targeting tumor neoepitopes that mediates immune cascade in murine tumor models***
Karin Lee, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

**AACR Special Conference: Tumor Immunology and Immunotherapy
November 27-30, 2018 • Loews Miami Beach Hotel • Miami Beach, Florida**

- 10:45 a.m.-11:00 a.m. **IL-35+ B cells establish immunosuppressive network in pancreatic ductal adenocarcinoma***
Bhalchandra Mirlekar, The Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill, Chapel Hill, NC
- 11:00 a.m.-11:30 a.m. **Dynamic interactions between myeloid and lymphoid cells regulate response to therapy in solid tumors**
Lisa M. Coussens
- 11:30 a.m.-12:00 p.m. **Tissue-specific immune tolerance promotes tumor-immune escape**
Niroshana Anandasabapathy, Weill Cornell Medical College, New York, NY
- 12:00 p.m.-12:30 p.m. **Repertoire and expression profiles and function of neoantigen-specific T cells**
Drew M. Pardoll, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD
- 12:30 p.m. Conclusion**

*Short talk from proffered abstract.